AngioDynamics (ANGO) investor relations material

Business transformation and strategic focus

• Shifted from slower, commodity-based markets to technology-driven, high-growth segments over the past five to six years, focusing on cardiovascular and interventional oncology platforms.

• Completed three divestitures and invested in three core future areas, simplifying the supply chain and expanding global regulatory approvals.

• Emphasized transparency and direct communication as key to unlocking further investor confidence and upside.

Financial performance and commercial momentum

• Fiscal year starts June 1; first two quarters of the current year exceeded guidance and expectations.

• Med Device segment remains profitable and supports transformation, while Med Tech segment is the primary growth driver.

• Med Tech platforms grew nearly 20% in the first six months, with gross margin and bottom-line profit ahead of expectations.

Med Tech segment: Product highlights and growth drivers

• Med Tech comprises arterial disease (Auryon), venous disease, and interventional oncology (NanoKnife).

• Auryon achieved over $60 million in annual revenue within five years, with 18 consecutive quarters of double-digit growth.

• Growth driven by new customer adoption, increased hospital penetration (now over 40% of revenue), and international expansion following CE mark approval.

• Auryon’s unique laser technology enables safe treatment of in-stent restenosis and potential future coronary applications; FDA pathway for CAD is a 3-4 year process.